

Daniel Aletaha

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8190186/publications.pdf>

Version: 2024-02-01

248
papers

44,057
citations

9786

73
h-index

2127

203
g-index

257
all docs

257
docs citations

257
times ranked

25392
citing authors

#	ARTICLE	IF	CITATIONS
1	2010 Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis and Rheumatism, 2010, 62, 2569-2581.	6.7	6,781
2	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Annals of the Rheumatic Diseases, 2017, 76, 960-977.	0.9	3,366
3	2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Annals of the Rheumatic Diseases, 2010, 69, 1580-1588.	0.9	2,994
4	Rheumatoid arthritis. Lancet, The, 2016, 388, 2023-2038.	13.7	2,989
5	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 685-699.	0.9	1,860
6	Treating rheumatoid arthritis to target: recommendations of an international task force. Annals of the Rheumatic Diseases, 2010, 69, 631-637.	0.9	1,711
7	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Annals of the Rheumatic Diseases, 2014, 73, 492-509.	0.9	1,688
8	Rheumatoid arthritis. Nature Reviews Disease Primers, 2018, 4, 18001.	30.5	1,441
9	EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Annals of the Rheumatic Diseases, 2010, 69, 964-975.	0.9	1,429
10	Diagnosis and Management of Rheumatoid Arthritis. JAMA - Journal of the American Medical Association, 2018, 320, 1360.	7.4	1,257
11	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.9	1,114
12	American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis and Rheumatism, 2011, 63, 573-586.	6.7	864
13	New therapies for treatment of rheumatoid arthritis. Lancet, The, 2007, 370, 1861-1874.	13.7	859
14	Acute phase reactants add little to composite disease activity indices for rheumatoid arthritis: validation of a clinical activity score. Arthritis Research, 2005, 7, R796.	2.0	838
15	American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials. Annals of the Rheumatic Diseases, 2011, 70, 404-413.	0.9	657
16	EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Annals of the Rheumatic Diseases, 2020, 79, 700.1-712.	0.9	609
17	Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Annals of the Rheumatic Diseases, 2018, 77, 3-17.	0.9	484
18	Remission and active disease in rheumatoid arthritis: Defining criteria for disease activity states. Arthritis and Rheumatism, 2005, 52, 2625-2636.	6.7	428

#	ARTICLE	IF	CITATIONS
19	The Simplified Disease Activity Index (SDAI) and the Clinical Disease Activity Index (CDAI): a review of their usefulness and validity in rheumatoid arthritis. <i>Clinical and Experimental Rheumatology</i> , 2005, 23, S100-8.	0.8	417
20	2016 update of the EULAR recommendations for the management of early arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 948-959.	0.9	393
21	Distinctions Between Diagnostic and Classification Criteria?. <i>Arthritis Care and Research</i> , 2015, 67, 891-897.	3.4	386
22	Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. <i>Nature Reviews Rheumatology</i> , 2015, 11, 276-289.	8.0	372
23	Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 811-818.	0.9	325
24	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 16-22.	0.9	275
25	Application of the DAREA/DAPSA score for assessment of disease activity in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1441-1447.	0.9	274
26	Depletion of Endothelial Progenitor Cells in the Peripheral Blood of Patients With Rheumatoid Arthritis. <i>Circulation</i> , 2005, 111, 204-211.	1.6	265
27	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Phase 2 methodological report. <i>Arthritis and Rheumatism</i> , 2010, 62, 2582-2591.	6.7	246
28	Measuring function in rheumatoid arthritis: Identifying reversible and irreversible components. <i>Arthritis and Rheumatism</i> , 2006, 54, 2784-2792.	6.7	241
29	Disease activity early in the course of treatment predicts response to therapy after one year in rheumatoid arthritis patients. <i>Arthritis and Rheumatism</i> , 2007, 56, 3226-3235.	6.7	225
30	EULAR definition of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 31-35.	0.9	224
31	2014 Update of the EULAR standardised operating procedures for EULAR-endorsed recommendations. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 8-13.	0.9	223
32	Multinational evidence-based recommendations for the diagnosis and management of gout: integrating systematic literature review and expert opinion of a broad panel of rheumatologists in the 3e initiative. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 328-335.	0.9	222
33	Discrepancies between patients and physicians in their perceptions of rheumatoid arthritis disease activity. <i>Arthritis and Rheumatism</i> , 2012, 64, 2814-2823.	6.7	218
34	Proposal for a new nomenclature of disease-modifying antirheumatic drugs: TableÂ1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 3-5.	0.9	212
35	SARS-CoV-2 vaccination in rituximab-treated patients: B cells promote humoral immune responses in the presence of T-cell-mediated immunity. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1345-1350.	0.9	211
36	EULAR definition of arthralgia suspicious for progression to rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 491-496.	0.9	209

#	ARTICLE	IF	CITATIONS
37	Evidence for treating rheumatoid arthritis to target: results of a systematic literature search. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 638-643.	0.9	203
38	A pilot risk model for the prediction of rapid radiographic progression in rheumatoid arthritis. <i>Rheumatology</i> , 2009, 48, 1114-1121.	1.9	198
39	Quantitative and qualitative deficiencies of regulatory T cells in patients with systemic lupus erythematosus (SLE). <i>International Immunology</i> , 2008, 20, 861-868.	4.0	188
40	Physical disability in rheumatoid arthritis is associated with cartilage damage rather than bone destruction. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 733-739.	0.9	159
41	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 71-87.	0.9	158
42	The 2010 American College of Rheumatology/European League Against Rheumatism classification criteria for rheumatoid arthritis: Methodological Report Phase I. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1589-1595.	0.9	152
43	Interleukin-6 receptor inhibition with tocilizumab and attainment of disease remission in rheumatoid arthritis: The role of acute-phase reactants. <i>Arthritis and Rheumatism</i> , 2011, 63, 43-52.	6.7	141
44	The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. <i>Best Practice and Research in Clinical Rheumatology</i> , 2007, 21, 663-675.	3.3	134
45	Minimal disease activity for rheumatoid arthritis: a preliminary definition. <i>Journal of Rheumatology</i> , 2005, 32, 2016-24.	2.0	132
46	Rheumatoid arthritis joint progression in sustained remission is determined by disease activity levels preceding the period of radiographic assessment. <i>Arthritis and Rheumatism</i> , 2009, 60, 1242-1249.	6.7	127
47	Anti-TNF in rheumatoid arthritis: an overview. <i>Wiener Medizinische Wochenschrift</i> , 2015, 165, 3-9.	1.1	125
48	The Definition and Measurement of Disease Modification in Inflammatory Rheumatic Diseases. <i>Rheumatic Disease Clinics of North America</i> , 2006, 32, 9-44.	1.9	124
49	Economic aspects of treatment options in rheumatoid arthritis: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 995-1003.	0.9	122
50	Joint damage in rheumatoid arthritis progresses in remission according to the Disease Activity Score in 28 joints and is driven by residual swollen joints. <i>Arthritis and Rheumatism</i> , 2011, 63, 3702-3711.	6.7	122
51	Side-by-Side Comparison of Three Fully Automated SARS-CoV-2 Antibody Assays with a Focus on Specificity. <i>Clinical Chemistry</i> , 2020, 66, 1405-1413.	3.2	122
52	Tocilizumab inhibits progression of joint damage in rheumatoid arthritis irrespective of its anti-inflammatory effects: disassociation of the link between inflammation and destruction. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 687-693.	0.9	119
53	Performance of the 2010 ACR/EULAR classification criteria for rheumatoid arthritis: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 114-123.	0.9	118
54	Impact of comorbidity on physical function in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 536-541.	0.9	117

#	ARTICLE	IF	CITATIONS
55	SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1355-1356.	0.9	116
56	EULAR definition of erosive disease in light of the 2010 ACR/EULAR rheumatoid arthritis classification criteria. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 479-481.	0.9	114
57	Comorbidity affects all domains of physical function and quality of life in patients with rheumatoid arthritis. <i>Rheumatology</i> , 2011, 50, 381-388.	1.9	109
58	Near misses of ACR/EULAR criteria for remission: effects of patient global assessment in Boolean and index-based definitions. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1702-1705.	0.9	109
59	Comparative effectiveness and safety of biological treatment options after tumour necrosis factor $\hat{\pm}$ inhibitor failure in rheumatoid arthritis: systematic review and indirect pairwise meta-analysis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1303-1308.	0.9	108
60	Remission in rheumatoid arthritis: benefit over low disease activity in patient-reported outcomes and costs. <i>Arthritis Research and Therapy</i> , 2014, 16, R56.	3.5	108
61	EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 20-33.	0.9	104
62	Forget personalised medicine and focus on abating disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 3-6.	0.9	98
63	Estimation of a numerical value for joint damage-related physical disability in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1058-1064.	0.9	95
64	Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study. <i>Lancet</i> , The, 2017, 389, 1206-1217.	13.7	94
65	Endothelial progenitor cells in active rheumatoid arthritis: effects of tumour necrosis factor and glucocorticoid therapy. <i>Annals of the Rheumatic Diseases</i> , 2007, 66, 1284-1288.	0.9	87
66	The pathogenesis of rheumatoid arthritis: new insights from old clinical data?. <i>Nature Reviews Rheumatology</i> , 2012, 8, 235-243.	8.0	86
67	Patient-reported Outcomes in Chronic Gout: A Report from OMERACT 10. <i>Journal of Rheumatology</i> , 2011, 38, 1452-1457.	2.0	84
68	Characteristics of difficult-to-treat rheumatoid arthritis: results of an international survey. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1705-1709.	0.9	83
69	Effectiveness profiles and dose dependent retention of traditional disease modifying antirheumatic drugs for rheumatoid arthritis. An observational study. <i>Journal of Rheumatology</i> , 2002, 29, 1631-8.	2.0	83
70	Definition of treatment response in rheumatoid arthritis based on the simplified and the clinical disease activity index. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1190-1196.	0.9	82
71	Response of elderly patients with rheumatoid arthritis to methotrexate or TNF inhibitors compared with younger patients. <i>Rheumatology</i> , 2009, 48, 1575-1580.	1.9	79
72	Superior efficacy of combination therapy for rheumatoid arthritis: Fact or fiction?. <i>Arthritis and Rheumatism</i> , 2005, 52, 2975-2983.	6.7	77

#	ARTICLE	IF	CITATIONS
73	Evaluation of the appropriateness of composite disease activity measures for assessment of psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 546-549.	0.9	76
74	Therapeutic strategies in early rheumatoid arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2005, 19, 163-177.	3.3	74
75	Rheumatoid factor, not antibodies against citrullinated proteins, is associated with baseline disease activity in rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2015, 17, 229.	3.5	73
76	Treatment-related improvement in physical function varies with duration of rheumatoid arthritis: a pooled analysis of clinical trial results. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 238-243.	0.9	71
77	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1999-2002.	0.9	71
78	The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. <i>Arthritis Research and Therapy</i> , 2008, 10, 208.	3.5	69
79	Rheumatoid factor determines structural progression of rheumatoid arthritis dependent and independent of disease activity. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 875-880.	0.9	69
80	Pro-Inflammatory Cytokines in Rheumatoid Arthritis: Pathogenetic and Therapeutic Aspects. <i>Clinical Reviews in Allergy and Immunology</i> , 2005, 28, 239-248.	6.5	67
81	Changes in patient characteristics in anti-tumour necrosis factor clinical trials for rheumatoid arthritis: results of an analysis of the literature over the past 16 years. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1631-1640.	0.9	63
82	Optimisation of a treat-to-target approach in rheumatoid arthritis: strategies for the 3-month time point. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 1479-1485.	0.9	63
83	Risk profiling for a refractory course of rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2019, 49, 211-217.	3.4	62
84	Rheumatoid arthritis and falls: the influence of disease activity. <i>Rheumatology</i> , 2012, 51, 2051-2057.	1.9	59
85	Development of a multimorbidity index: Impact on quality of life using a rheumatoid arthritis cohort. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 167-173.	3.4	58
86	Developments in the clinical understanding of rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2009, 11, 204.	3.5	56
87	Sonographic Joint Assessment in Rheumatoid Arthritis: Associations With Clinical Joint Assessment During a State of Remission. <i>Arthritis and Rheumatism</i> , 2013, 65, 2005-2014.	6.7	56
88	Precision medicine and management of rheumatoid arthritis. <i>Journal of Autoimmunity</i> , 2020, 110, 102405.	6.5	56
89	Rheumatoid arthritis near remission: clinical rather than laboratory inflammation is associated with radiographic progression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1975-1980.	0.9	54
90	Fever of unknown origin (FUO) revised. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 796-801.	1.9	54

#	ARTICLE	IF	CITATIONS
91	Development and Validation of Modified Disease Activity Scores in Rheumatoid Arthritis: Superior Correlation With Magnetic Resonance Imaging–Detected Synovitis and Radiographic Progression. <i>Arthritis and Rheumatology</i> , 2014, 66, 794-802.	5.6	52
92	Relationship between disease activity indices and their individual components and radiographic progression in RA: a systematic literature review. <i>Rheumatology</i> , 2015, 54, 994-1007.	1.9	51
93	Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 1269-1275.	0.9	50
94	Follow-up standards and treatment targets in rheumatoid arthritis: results of a questionnaire at the EULAR 2008. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 575-578.	0.9	47
95	The need for new classification criteria for rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , 2005, 52, 3333-3336.	6.7	46
96	The importance of reporting disease activity states in rheumatoid arthritis clinical trials. <i>Arthritis and Rheumatism</i> , 2008, 58, 2622-2631.	6.7	46
97	Remission in rheumatoid arthritis: missing objectives by using inadequate DAS28 targets. <i>Nature Reviews Rheumatology</i> , 2019, 15, 633-634.	8.0	45
98	Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 241-244.	0.9	44
99	Additional heterologous versus homologous booster vaccination in immunosuppressed patients without SARS-CoV-2 antibody seroconversion after primary mRNA vaccination: a randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 687-694.	0.9	43
100	Testing different thresholds for patient global assessment in defining remission for rheumatoid arthritis: are the current ACR/EULAR Boolean criteria optimal?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 445-452.	0.9	42
101	Predictors, Risk Factors, and Incidence Rates of Psoriatic Arthritis Development in Psoriasis Patients: A Systematic Literature Review and Meta-Analysis. <i>Rheumatology and Therapy</i> , 2021, 8, 1519-1534.	2.3	42
102	Tocilizumab in patients with new onset polymyalgia rheumatica (PMR-SPARE): a phase 2/3 randomised controlled trial. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 838-844.	0.9	41
103	Remission by composite scores in rheumatoid arthritis: are ankles and feet important?. <i>Arthritis Research and Therapy</i> , 2007, 9, R72.	3.5	39
104	The Simplified Disease Activity Index and Clinical Disease Activity Index to Monitor Patients in Standard Clinical Care. <i>Rheumatic Disease Clinics of North America</i> , 2009, 35, 759-772.	1.9	39
105	Therapeutic implications of autoantibodies in rheumatoid arthritis. <i>RMD Open</i> , 2016, 2, e000009.	3.8	39
106	Brief Report: Remission Rates With Tofacitinib Treatment in Rheumatoid Arthritis: A Comparison of Various Remission Criteria. <i>Arthritis and Rheumatology</i> , 2017, 69, 728-734.	5.6	39
107	The effects of structural damage on functional disability in psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 2038-2045.	0.9	38
108	The 2021 EULAR/American College of Rheumatology points to consider for diagnosis, management and monitoring of the interleukin-1 mediated autoinflammatory diseases: cryopyrin-associated periodic syndromes, tumour necrosis factor receptor-associated periodic syndrome, mevalonate kinase deficiency, and deficiency of the interleukin-1 receptor antagonist. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 907-921.	0.9	38

#	ARTICLE	IF	CITATIONS
109	Predictors for influenza vaccine acceptance among patients with inflammatory rheumatic diseases. <i>Vaccine</i> , 2018, 36, 4875-4879.	3.8	37
110	Early rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2006, 18, 282-288.	4.3	36
111	Development of EULAR recommendations for the reporting of clinical trial extension studies in rheumatology. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 963-969.	0.9	36
112	Disease activity level, remission and response in established rheumatoid arthritis: Performance of various criteria sets in an observational cohort, treated with anti-TNF agents. <i>BMC Musculoskeletal Disorders</i> , 2009, 10, 41.	1.9	35
113	Risk of Developing Additional Immune-Mediated Manifestations: A Retrospective Matched Cohort Study. <i>Advances in Therapy</i> , 2019, 36, 1672-1683.	2.9	34
114	Effect of disease duration and prior disease-modifying antirheumatic drug use on treatment outcomes in patients with rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1609-1615.	0.9	33
115	Activity assessments in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2008, 20, 306-313.	4.3	32
116	Monitoring rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2011, 23, 252-258.	4.3	32
117	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2020, 15, e0233781.	2.5	32
118	Histone deacetylase 1 (HDAC1): A key player of T cell-mediated arthritis. <i>Journal of Autoimmunity</i> , 2020, 108, 102379.	6.5	31
119	EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1286-1298.	0.9	31
120	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology points to consider for diagnosis and management of autoinflammatory type I interferonopathies: CANDLE/PRAAS, SAVI and AGS. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 601-613.	0.9	31
121	An overview of psoriatic arthritis “epidemiology, clinical features, pathophysiology and novel treatment targets. <i>Wiener Klinische Wochenschrift</i> , 2016, 128, 791-795.	1.9	30
122	Can disease activity in patients with psoriatic arthritis be adequately assessed by a modified Disease Activity index for PSoriatic Arthritis (DAPSA) based on 28 joints?. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1736-1741.	0.9	30
123	2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 707-713.	0.9	30
124	Disease activity and response assessment in psoriatic arthritis using the Disease Activity index for PSoriatic Arthritis (DAPSA). A brief review. <i>Clinical and Experimental Rheumatology</i> , 2015, 33, S48-50.	0.8	30
125	Cardiovascular Risk Factors and Comorbidities in Patients with Hyperuricemia and/or Gout: A Systematic Review of the Literature. <i>Journal of rheumatology Supplement</i> , The, 2014, 92, 9-14.	2.2	29
126	Predictors of successful discontinuation of biologic and targeted synthetic DMARDs in patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. <i>Rheumatology</i> , 2020, 59, 324-334.	1.9	29

#	ARTICLE	IF	CITATIONS
127	Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 884-890.	0.9	28
128	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 276-284.	3.4	25
129	Rituximab dissociates the tight link between disease activity and joint damage in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, 7-12.	0.9	24
130	Different Rating of Global Rheumatoid Arthritis Disease Activity in Rheumatoid Arthritis Patients With Multiple Morbidities. <i>Arthritis and Rheumatology</i> , 2017, 69, 720-727.	5.6	24
131	Physical function continues to improve when clinical remission is sustained in rheumatoid arthritis patients. <i>Arthritis Research and Therapy</i> , 2015, 17, 203.	3.5	23
132	Comparative Assessment of the Different American College of Rheumatology/European League Against Rheumatism Remission Definitions for Rheumatoid Arthritis for Their Use as Clinical Trial End Points. <i>Arthritis and Rheumatology</i> , 2017, 69, 518-528.	5.6	23
133	Prevention, screening, assessing and managing of non-adherent behaviour in people with rheumatic and musculoskeletal diseases: systematic reviews informing the 2020 EULAR points to consider. <i>RMD Open</i> , 2020, 6, e001432.	3.8	23
134	The 2021 European Alliance of Associations for Rheumatology/American College of Rheumatology Points to Consider for Diagnosis and Management of Autoinflammatory Type I Interferonopathies: <scp>CANDLE</scp>/<scp>PRAAS</scp>, <scp>SAVI</scp>, and <scp>AGS</scp>. <i>Arthritis and Rheumatology</i> , 2022, 74, 735-751.	5.6	23
135	Monotherapy with biologic disease-modifying anti-rheumatic drugs in rheumatoid arthritis: Table 1. <i>Rheumatology</i> , 2016, 56, kew271.	1.9	22
136	Rheumatoid arthritis disease activity and the risk of aseptic arthroplasty loosening. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 245-251.	3.4	20
137	Importance of the second SARS-CoV-2 vaccination dose for achieving serological response in patients with rheumatoid arthritis and seronegative spondyloarthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 416-421.	0.9	19
138	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. <i>Arthritis Research and Therapy</i> , 2018, 20, 174.	3.5	18
139	Workforce requirements in rheumatology: a systematic literature review informing the development of a workforce prediction risk of bias tool and the EULAR points to consider. <i>RMD Open</i> , 2018, 4, e000756.	3.8	17
140	Disease activity assessment in patients with psoriatic arthritis. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 401-414.	3.3	17
141	Achieving Clinical Remission for Patients With Rheumatoid Arthritis. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 457.	7.4	17
142	Compression Test (Gaenslen's Squeeze Test) Positivity, Joint Tenderness, and Disease Activity in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2013, 65, 653-657.	3.4	16
143	EULAR "points to consider"™ for the conduction of workforce requirement studies in rheumatology. <i>RMD Open</i> , 2018, 4, e000780.	3.8	16
144	Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumab. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 874-882.	0.9	16

#	ARTICLE	IF	CITATIONS
145	The role of ultrasound and magnetic resonance imaging for treat to target in rheumatoid arthritis and psoriatic arthritis. <i>Rheumatology</i> , 2019, 58, 2091-2098.	1.9	15
146	Intercepting psoriatic arthritis in patients with psoriasis: buy one get one free?. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 7-10.	0.9	15
147	Clinical meaning and implications of serum hemoglobin levels in patients with rheumatoid arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2017, 47, 193-198.	3.4	14
148	A core set of risk factors in individuals at risk of rheumatoid arthritis: a systematic literature review informing the EULAR points to consider for conducting clinical trials and observational studies in individuals at risk of rheumatoid arthritis. <i>RMD Open</i> , 2021, 7, e001768.	3.8	14
149	Response to SARS-CoV-2 vaccination in systemic autoimmune rheumatic disease depends on immunosuppressive regimen: a matched, prospective cohort study. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1017-1022.	0.9	14
150	The 2021 EULAR/American College of Rheumatology Points to Consider for Diagnosis, Management and Monitoring of the Interleukin-1 Mediated Autoinflammatory Diseases: Cryopyrin-Associated Periodic Syndromes, Tumour Necrosis Factor Receptor-Associated Periodic Syndrome, Mevalonate Kinase Deficiency, and Deficiency of the Interleukin-1 Receptor Antagonist. <i>Arthritis and Rheumatology</i> , 2022, 74, 1102-1121.	5.6	14
151	Pooled indices to measure rheumatoid arthritis activity: a good reflection of the physician's mind?. <i>Arthritis Research and Therapy</i> , 2006, 8, 102.	3.5	13
152	The American College of Rheumatology N (ACR-N) debate: Going back into the middle of the tunnel? Comment on the articles by Siegel and Zhen and by Boers. <i>Arthritis and Rheumatism</i> , 2006, 54, 377-378.	6.7	13
153	Inhibition of radiographic progression in psoriatic arthritis by adalimumab independent of the control of clinical disease activity. <i>Rheumatology</i> , 2019, 58, 1025-1033.	1.9	13
154	An updated matrix to predict rapid radiographic progression of early rheumatoid arthritis patients: pooled analyses from several databases. <i>Rheumatology</i> , 2020, 59, 1842-1852.	1.9	13
155	Defining remission and treatment success using the DAPSA score: response to letter by Helliwell and Coates. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, e67-e67.	0.9	12
156	Analysis of gene expression in rheumatoid arthritis and related conditions offers insights into sex-bias, gene biotypes and co-expression patterns. <i>PLoS ONE</i> , 2019, 14, e0219698.	2.5	12
157	Biobetters in patients with immune-mediated inflammatory disorders: An international Delphi consensus. <i>Autoimmunity Reviews</i> , 2021, 20, 102849.	5.8	12
158	Torque Teno Virus quantification for monitoring of immunomodulation with biologic compounds in the treatment of rheumatoid arthritis. <i>Rheumatology</i> , 2022, 61, 2815-2825.	1.9	12
159	Multicentre study to improve clinical interpretation of rheumatoid factor and anti-citrullinated protein/peptide antibodies test results. <i>RMD Open</i> , 2022, 8, e002099.	3.8	12
160	Capturing real-life patient care in psoriatic arthritis and its risks: the challenge of analysing registry data. <i>Arthritis Research and Therapy</i> , 2009, 11, 112.	3.5	11
161	Algorithm for Identification of Undifferentiated Peripheral Inflammatory Arthritis: A Multinational Collaboration Through the 3e Initiative. <i>Journal of rheumatology Supplement</i> , The, 2011, 87, 54-58.	2.2	11
162	Can we improve the performance and reporting of investigator-initiated clinical trials? Rheumatoid arthritis as an example: Table A1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 1755-1760.	0.9	11

#	ARTICLE	IF	CITATIONS
163	Reliability of patient-reported outcomes in rheumatoid arthritis patients: an observational prospective study. <i>Rheumatology</i> , 2016, 55, 41-48.	1.9	11
164	Perceptions and experiences of individuals at-risk of rheumatoid arthritis (RA) knowing about their risk of developing RA and being offered preventive treatment: systematic review and thematic synthesis of qualitative studies. <i>Annals of the Rheumatic Diseases</i> , 2021, , annrheumdis-2021-221160.	0.9	11
165	Pre-arthritis: a concept whose time has come. <i>Future Rheumatology</i> , 2006, 1, 1-4.	0.2	10
166	The use of data from early arthritis clinics for clinical research. <i>Best Practice and Research in Clinical Rheumatology</i> , 2009, 23, 117-123.	3.3	10
167	Chronicity of rheumatoid arthritis affects the responsiveness of physical function, but not of disease activity measures in rheumatoid arthritis clinical trials. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 532-537.	0.9	10
168	<p>Treatment Mode Preferences in Psoriatic Arthritis: A Qualitative Multi-Country Study</p>. <i>Patient Preference and Adherence</i> , 2020, Volume 14, 949-961.	1.8	10
169	Efficacy and safety of filgotinib in methotrexate-naïve patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3. <i>RMD Open</i> , 2021, 7, e001621.	3.8	10
170	The EULAR points to consider for health professionals undertaking musculoskeletal ultrasound for rheumatic and musculoskeletal diseases. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 311-313.	0.9	9
171	Predicting achievement of the treatment targets at 6 months from 3-month response levels in rheumatoid arthritis: data from real-life follow-up in the NOR-DMARD study. <i>RMD Open</i> , 2018, 4, e000773.	3.8	9
172	Synovitis in rheumatoid arthritis detected by grey scale ultrasound predicts the development of erosions over the next three years. <i>Rheumatology</i> , 2020, 59, 1556-1565.	1.9	9
173	Efficacy outcomes in phase 2 and phase 3 randomized controlled trials in rheumatology. <i>Nature Medicine</i> , 2020, 26, 974-980.	30.7	9
174	Long-term safety and efficacy of sirukumab for patients with rheumatoid arthritis who previously received sirukumab in randomised controlled trials (SIRROUND-LTE). <i>RMD Open</i> , 2021, 7, e001465.	3.8	9
175	TNFR2 is critical for TNF-induced rheumatoid arthritis fibroblast-like synoviocyte inflammation. <i>Rheumatology</i> , 2022, 61, 4535-4546.	1.9	9
176	Clinical and economic analysis of outcomes of dose tapering or withdrawal of tumor necrosis factor-α inhibitors upon achieving stable disease activity in rheumatoid arthritis patients. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 451-458.	1.9	8
177	A critical review of the reproductive safety of Leflunomide. <i>Clinical Rheumatology</i> , 2020, 39, 607-612.	2.2	8
178	Presence of anti-acetylated peptide antibodies (AAPA) in inflammatory arthritis and other rheumatic diseases suggests discriminative diagnostic capacity towards early rheumatoid arthritis. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2021, 13, 1759720X2110225.	2.7	8
179	Threats to validity of observational studies on disease-modifying antirheumatic drug therapies for rheumatoid arthritis: New aspects after the fall of the pyramid and the rise of new therapeutics. <i>Current Rheumatology Reports</i> , 2003, 5, 409-412.	4.7	7
180	New insights into the measurement of disease activity in rheumatoid arthritis. <i>Current Opinion in Rheumatology</i> , 2015, 27, 268-272.	4.3	7

#	ARTICLE	IF	CITATIONS
181	Effect of disease duration and other characteristics on efficacy outcomes in clinical trials of tocilizumab for rheumatoid arthritis. <i>Rheumatology</i> , 2021, 60, 682-691.	1.9	7
182	Reexamining remission definitions in rheumatoid arthritis: considering the twenty-eightâ€“joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>RMD Open</i> , 2021, 7, e002034.	3.8	7
183	Re-examining remission definitions in rheumatoid arthritis: considering the 28-Joint Disease Activity Score, C-reactive protein level and patient global assessment. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 4-7.	0.9	7
184	Information technology concerning SDAI and CDAI. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, S45-S48.	0.8	7
185	Glucocorticoid Effect on Radiographic Progression in Placebo Arms of Rheumatoid Arthritis Biologics Trials. <i>Journal of Rheumatology</i> , 2016, 43, 1024-1026.	2.0	6
186	Disease activity improvements with optimal discriminatory ability between treatment arms: applicability in early and established rheumatoid arthritis clinical trials. <i>Arthritis Research and Therapy</i> , 2019, 21, 231.	3.5	6
187	Differences in disease activity measures in patients with rheumatoid arthritis who achieved DAS, SDAI, or CDAI remission but not Boolean remission. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 643-644.	3.4	6
188	Trajectory clusters of radiographic progression in patients with rheumatoid arthritis: associations with clinical variables. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 175-183.	0.9	6
189	SARS-CoV-2 and the rheumatology patient: the last 12 months and a boost in the future. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1249-1251.	0.9	6
190	Baseline predictors of different types of treatment success in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 153-158.	0.9	6
191	Impact of pre-existing background therapy on placebo responses in randomised controlled clinical trials of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 1374-1378.	0.9	6
192	IgA rheumatoid factor in rheumatoid arthritis. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 1617-1626.	2.3	6
193	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering Disease Activity Score in 28 Joints, Câ€“Reactive Protein, and Patient Global Assessment. <i>ACR Open Rheumatology</i> , 2022, 4, 123-127.	2.1	5
194	Big data analyses and individual health profiling in the arena of rheumatic and musculoskeletal diseases (RMDs). <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2022, 14, 1759720X2211059.	2.7	5
195	The many faces of psoriatic arthritis â€“ a challenge to treatment to target?. <i>Reumatologia</i> , 2016, 1, 1-2.	1.1	4
196	Early response to therapy predicts 6-month and 1-year disease activity outcomes in psoriatic arthritis patients. <i>Rheumatology</i> , 2018, 57, 969-976.	1.9	4
197	Are we failing patients in our assessment of treatment failure?. <i>Rheumatology</i> , 2019, 58, 561-562.	1.9	4
198	Response to: â€“Correspondence on â€“SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune responseâ€™â€™ by Westhoff <i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, e163-e163.	0.9	4

#	ARTICLE	IF	CITATIONS
199	Response to: Correspondence on “SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response” by Bonelli <i>et al</i> . Annals of the Rheumatic Diseases, 2021, 80, e167-e167.	0.9	4
200	In vitro evaluation of disease-modifying antirheumatic drugs against rheumatoid arthritis associated pathogens of the oral microflora. RMD Open, 2021, 7, e001737.	3.8	4
201	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. Arthritis and Rheumatology, 2022, 74, 5-9.	5.6	4
202	Baricitinib further enhances disease-modifying effects by uncoupling the link between disease activity and joint structural progression in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases, 2022, 81, 622-631.	0.9	4
203	Developing guidelines for ultrarare rheumatic disorders: a bumpy ride. Annals of the Rheumatic Diseases, 2022, 81, 1203-1205.	0.9	4
204	To DAPSA or not to DAPSA? That is not the question. Annals of the Rheumatic Diseases, 2019, 78, e61-e61.	0.9	3
205	Pseudoerosions of Hands and Feet in Rheumatoid Arthritis: Anatomic Concepts and Redefinition. Journal of Clinical Medicine, 2019, 8, 2174.	2.4	3
206	Genetic risk scores in inflammatory arthritis: a new era?. Nature Reviews Rheumatology, 2020, 16, 545-546.	8.0	3
207	Reexamining Remission Definitions in Rheumatoid Arthritis: Considering the Twenty-Eight Joint Disease Activity Score, C-Reactive Protein Level, and Patient Global Assessment. Arthritis Care and Research, 2022, 74, 1-5.	3.4	3
208	Role of clinical and biochemical inflammation in structural progression of patients with psoriatic arthritis. RMD Open, 2021, 7, e002038.	3.8	3
209	Analysis of combined deficiency of interleukin-1 and -6 versus single deficiencies in TNF-mediated arthritis and systemic bone loss. Bone and Joint Research, 2022, 11, 484-493.	3.6	3
210	Management of rheumatoid arthritis: what happens and what does not happen in real life. Rheumatology International, 2016, 36, 167-168.	3.0	2
211	Outcome Measurement in Rheumatoid Arthritis: Disease Activity. , 2009, , 225-230.		2
212	Evaluation and outcomes of patients with rheumatoid arthritis. , 2015, , 790-801.		2
213	Reflections on a contemporary European tragedy. Annals of the Rheumatic Diseases, 2022, 81, 747-748.	0.9	2
214	Standardisation of ACPA tests: evaluation of a new candidate reference preparation. Annals of the Rheumatic Diseases, 2022, 81, 1379-1384.	0.9	2
215	The health assessment questionnaire in routine clinical practice. Nature Clinical Practice Rheumatology, 2007, 3, 122-123.	3.2	1
216	Monitoring disease activity in rheumatoid arthritis: an imperative. Future Rheumatology, 2008, 3, 99-102.	0.2	1

#	ARTICLE	IF	CITATIONS
217	Does Triple Conventional Synthetic Disease-Modifying Antirheumatic Drug Therapy Improve upon Methotrexate as the Initial Treatment of Choice for a Rheumatoid Arthritis Patient?. Rheumatic Disease Clinics of North America, 2019, 45, 315-324.	1.9	1
218	Missing pebble in the mosaic of rheumatic diseases and mental health: younger does not always mean happier. Annals of the Rheumatic Diseases, 2019, 78, e54-e54.	0.9	1
219	Response to: "Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis" by Bugatti et al. Annals of the Rheumatic Diseases, 2022, 81, e56-e56.	0.9	1
220	Doubtful swelling on clinical examination reflects synovitis in rheumatoid arthritis. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2093348.	2.7	1
221	Is Methotrexate as Efficacious as Etanercept in Psoriatic Arthritis Patients? Comment on the Article by Mease et al. Arthritis and Rheumatology, 2020, 72, 1227-1229.	5.6	1
222	Response to: "Correspondence on "Role of joint damage, malalignment and inflammation in articular tenderness in rheumatoid arthritis, psoriatic arthritis and osteoarthritis" by Dumoulin et al. Annals of the Rheumatic Diseases, 2021, , annrhumdis-2021-220922.	0.9	1
223	Evaluation and outcomes of patients with rheumatoid arthritis. , 2011, , 941-954.e1.		1
224	The undifferentiated arthritis dilemma: the story continues. Nature Reviews Rheumatology, 2022, 18, 189-190.	8.0	1
225	EMerging EULAR NETwork (EMEUNET): a remarkable foundation for the future. RMD Open, 2021, 7, e001962.	3.8	1
226	Is computer-assisted management necessary for patients with early rheumatoid arthritis?. Nature Clinical Practice Rheumatology, 2008, 4, 338-339.	3.2	0
227	Reply. Arthritis and Rheumatology, 2014, 66, 3245-3246.	5.6	0
228	How FABulous is PEGgy? Certolizumab Pegol from the Bench to the Patients. BioDrugs, 2014, 28, 3-4.	4.6	0
229	08.28...The prognostic value of iga autoantibodies (rheumatoid factor and acpa) for prediction of the therapeutic response to anti-tnf therapy in patients with rheumatoid arthritis. , 2017, , .		0
230	The slippery road of adherence in chronically ill individuals. Rheumatology, 2020, 59, 9-11.	1.9	0
231	AB0277...EFFECT OF DISEASE DURATION AND OTHER PATIENT BASELINE CHARACTERISTICS ON OUTCOMES IN TOCILIZUMAB-TREATED RHEUMATOID ARTHRITIS PATIENTS: A POOLED ANALYSIS. , 2019, , .		0
232	SAT0160...PREFERENCES OF EUROPEAN RHEUMATOLOGISTS ON THE DISCONTINUATION OF BIOLOGICAL DISEASE-MODIFYING ANTIRHEUMATIC DRUGS IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
233	SAT0104...INITIAL EVIDENCE FOR THE NEED OF A DUAL TREAT-TO-TARGET STRATEGY IN PATIENTS WITH RHEUMATOID ARTHRITIS. , 2019, , .		0
234	THU0431...FREQUENCY OF TENDON INVOLVEMENT AND ITS EFFECT ON HAND FUNCTION IN HAND OSTEOARTHRITIS. , 2019, , .		0

235	FRI0162â€¦BASELINE CHARACTERISTICS AND OUTCOMES IN PATIENTS WITH ANAEMIA IN CLINICAL STUDIES OF TOFACITINIB IN RHEUMATOID ARTHRITIS. , 2019, , .		0
236	AB0417â€¦EFFICACY AND SAFETY OF TOFACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS ACCORDING TO DURATION OF PRIOR CSDMARD TREATMENT AND NUMBER OF PRIOR CSDMARDS: A POST HOC ANALYSIS OF PHASE 3 AND PHASE 3B/4 TRIALS. , 2019, , .		0
237	SAT0061â€¦IMPORTANT ROLE OF CD11C+ CELLSIN INFLAMMATORY ARTHRITIS. , 2019, , .		0
238	THU0133â€¦TENDERNESS CAN BE REGARDED AS A SIGN OF INFLAMMATION IN RHEUMATOID ARTHRITIS. , 2019, , .		0
239	Treating Rheumatic Diseases to Target: A Story of Success. Rheumatic Disease Clinics of North America, 2019, 45, xi-xii.	1.9	0
240	P281â€¦52-Week efficacy and safety of ixekizumab in r-axSpA/AS patients naÃve to biologic treatments or with prior inadequate response/intolerance to tumor necrosis factor inhibitors. Rheumatology, 2020, 59, .	1.9	0
241	Response to: â€Comment on â€Implication of baseline levels and early changes of C-reactive protein for subsequent clinical outcomes of patients with rheumatoid arthritis treated with tocilizumabâ€â€TMâ€ by Pethoe-Schramm<i>et al</i>. Annals of the Rheumatic Diseases, 2022, 81, e137-e137.	0.9	0
242	Targeting p19 in psoriatic arthritis: more than just another therapeutic approach?. Lancet, The, 2020, 395, 1091-1093.	13.7	0
243	P178â€¦The impact of peripheral articular manifestations on the efficacy of ixekizumab in patients with radiographic axial spondyloarthritis. Rheumatology, 2021, 60, .	1.9	0
244	Can imaging help unravel pain in psoriatic arthritis?. Rheumatology, 2021, , .	1.9	0
245	Message from the new EULAR President and Steering Group. Annals of the Rheumatic Diseases, 2021, 80, 1266-1267.	0.9	0
246	Reply. Arthritis Care and Research, 2022, 74, 502-503.	3.4	0
247	Reply. ACR Open Rheumatology, 2022, 4, 269-270.	2.1	0